Mirati therapeutics, inc. (MRTX)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Operating activities:
Net loss

-86,655

-72,376

-54,273

-45,695

-40,912

-28,272

-27,568

-27,869

-14,709

-17,895

-16,350

-18,339

-17,846

-19,722

-19,421

-22,061

-21,914

-18,417

-18,741

-15,446

-11,940

-10,387

-8,617

-11,038

-13,656

-11,233

-29,397

-8,012

-4,217

Non-cash adjustments reconciling net loss to operating cash flows:
Depreciation

100

0

100

56

44

75

20

39

41

46

47

46

45

41

38

43

58

59

53

56

44

45

38

38

78

66

41

42

22

Accretion of discount on investments

520

603

854

1,047

917

563

381

214

162

34

54

107

71

-1

19

-11

-14

-657

69

152

99

95

126

146

167

0

0

0

0

Share-based compensation expense

21,567

16,711

15,106

12,589

11,131

4,262

4,058

3,874

3,660

1,318

1,479

2,223

1,766

2,538

2,760

2,288

3,038

2,342

2,804

2,792

2,316

2,228

2,591

1,285

946

726

852

-217

462

Change in fair value of warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-27

-1,907

976

5,475

3,190

20,596

384

-4,371

Change in restructuring costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

13

0

0

0

0

Lease incentive liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-19

-16

-18

Changes in operating assets and liabilities:
Other current assets

100

-1,079

253

4,785

1,528

385

73

-1,008

-502

1,357

-2

2,758

-704

317

778

-506

-843

50

1,009

-1,150

-188

716

894

-918

517

-397

206

166

-315

Other long-term assets

331

502

-109

2,753

1,229

155

20

159

25

-2,001

0

-895

-710

125

739

395

0

-

-

-

-

-114

416

24

0

-

-

-

-

Accounts payable, accrued liabilities, deferred revenue and other liabilities

6,909

13,696

7,234

3,168

-1,071

4,274

3,761

2,140

2,745

2,155

-215

423

-3,540

1,461

-139

2,964

1,009

-34

2,667

2,219

-482

40

-538

1,953

-1,304

-1,351

2,039

-1,223

467

Cash flows used in operating activities

-59,004

-41,902

-32,874

-38,468

-34,482

-20,795

-20,172

-21,181

-7,948

-13,766

-15,091

-17,617

-18,232

-16,123

-18,298

-16,644

-16,952

-16,030

-15,870

-9,039

-9,775

-8,587

-9,617

-5,746

-8,798

-7,712

-5,195

-9,208

-7,340

Investing activities:
Purchases of short-term investments

230,384

72,113

245,449

85,208

127,458

100,020

4,439

48,516

102,820

5,455

8,679

23,114

63,310

3,008

17,581

27,883

21,797

63,930

0

5,045

35,979

1,500

3,027

1,518

4,423

42,683

3,334

6,370

16,021

Security deposit, restricted cash equivalents and marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

9

-33

56

Sales and maturities of short-term investments

108,381

66,506

117,534

79,350

92,250

36,423

33,237

22,750

17,742

16,500

22,450

30,938

22,100

21,785

31,157

34,248

21,530

19,250

17,300

13,100

4,880

11,480

9,000

7,550

7,043

2,251

6,432

14,358

16,097

Purchases of property, plant, and equipment

224

1,332

151

69

0

-

-

-

-

-

-

-

-

133

18

0

45

33

-1

279

18

66

56

262

2

8

40

66

90

Cash flows used in investing activities

-122,227

-6,939

-128,066

-5,927

-35,208

-63,683

28,762

-25,766

-85,078

11,044

13,771

7,744

-41,210

18,644

13,558

6,365

-312

-44,713

17,301

7,776

-31,117

9,914

5,917

5,770

2,618

-40,404

3,049

7,955

-70

Financing activities:
Proceeds from issuance of common stock, net of issuance costs

323,977

20

0

219,927

107,883

0

3

130,660

0

86,714

0

0

66,816

0

0

0

0

4

94,928

0

48,361

0

0

0

0

-

-

-

-

Proceeds from issuances under employee stock purchase plan

-

-

-

-

-

240

0

202

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercise of common stock options and warrants

15,200

3,101

1,072

1,600

2,700

222

2,154

1,481

5,890

2,854

2,149

0

0

0

0

29

2,326

80

142

85

245

351

100

174

262

539

22

0

0

Proceeds from disgorgement of shareholders' short-swing profits

41

0

0

0

1,050

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows provided by financing activities

339,201

3,473

1,072

221,882

111,601

462

2,157

132,343

5,890

89,641

2,149

71

66,816

60

0

266

2,326

355

95,071

335

48,606

351

100

174

262

54,735

22

0

0

Increase in cash, cash equivalents and restricted cash

157,970

-45,368

-159,868

177,487

41,911

-84,016

10,747

85,396

-87,136

86,919

829

-9,802

7,374

2,581

-4,740

-10,013

-14,938

-60,388

96,502

-928

7,714

1,678

-3,600

198

-5,918

6,619

-2,124

-1,253

-7,410

Supplemental disclosures of non-cash investing activities:
Purchases of property, plant, and equipment included within accounts payable and accrued liabilities

408

-

-

-

0

-

-

-

-

-

-

-

54

-

-

-

0

-

-

-

197

-

30

-21

42

-

-

-

-